Author | Benjamin P. Saylor


FDA grants fast track designation for oral mCRPC agent

September 16, 2020

The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.

Microhematuria guideline emphasizes risk-stratified approach

July 31, 2020

A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.

FDA approves additional recommended dosage for anti-PD-1 therapy

May 13, 2020

The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.

Dr. Thrasher discusses COVID-19's impact on the ABU, telemedicine, research

April 28, 2020

J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.